ACT-A: put words into action to combat Covid-19

ACT-A, the global collaboration to respond to the Covid-19 pandemic, can and must do more to effectively combat this international health crisis. It must use its leverage to significantly improve equitable access to vaccines, therapeutics and diagnostics, and establish adequate funding of health systems in order to implement these commodities. Wemos fully supports the urgent recommendations on these matters of the Platform for Civil Society and Community Representatives to ACT-A.

Neglecting fundamental questions

In ACT-A (Access to Covid-19 Tools Accelerator), leading global health agencies (Global Fund, WHO, World Bank, etc.) collaborate with governments, civil society and industry to accelerate development and distribution of medical products against Covid-19. Recent evaluations on its work resulted in a review exploring possibilities to enhance its performance.

According to the ACT-A civil society representatives, the review has neglected fundamental questions and lacks input from those most affected by the pandemic. Therefore, they have published a statement holding recommendations for ACT-A to move forward.

Equal access to medical products

ACT-A consists of the most influential organisations in achieving equitable access to medical products against Covid-19. Nevertheless, the harsh reality is that many low- and middle-income countries still experience dire vaccine shortages.

The civil society representatives therefore call upon ACT-A to put words into action and make serious work of its purpose. One of their recommendations is that ACT-A must use its power to stimulate temporary waiving of intellectual property rights (through the so-called TRIPS waiver) and sharing of know-how and technology by pharmaceutical companies in order to maximise vaccine production.

Investing in health systems

Distribution of medical products against Covid-19 requires strong health systems with trained health workers to implement them. The civil society representatives believe that ACT-A does not recognize this matter. They urge ACT-A to prioritise investments in recruitment, training and remuneration of health workers, particularly in low- and middle-income countries.

Meaningful involvement

The civil society platform furthermore states that a lack of meaningful involvement of low- and middle-income country representatives in the decision-making, is at the root of the current shortcomings of ACT-A. So far, ACT-A has primarily turned to organisations and experts from high-income countries to develop and review ACT-A initiatives.

This approach is both demeaning and ineffective. As low- and middle-income countries are affected most by the pandemic, their involvement in decision-making is crucial to ensure that initiatives meet the actual needs.

Read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News items

Milestone: research institute shares patents and know-how globally through C-TAP


Wemos is delighted that the Spanish National Research Council (CSIC) shares its intellectual property and know-how for the production of its Covid-19 diagnostic tool with the Covid-19 Technology Access Pool (C-TAP) of the World Health Organization (WHO). As such, CSIC permits all qualified manufacturers worldwide to make the product and distribute it to any country in the world, royalty-free for low- and middle-income countries. This is the first global, non-exclusive license for a Covid-19 innovation and thus a milestone for equal access to medical products.

Continue reading

Pfizer’s knowledge sharing on antiviral is positive step, but more is needed


The US pharmaceutical company Pfizer will share its intellectual property and know-how for the production of its Covid-19 pill in the Medicines Patent Pool (MPP). The company is following the example of Merck & Co (MSD) that recently announced the same. This is an important step in the right direction to enhance global access to medical products against Covid-19. Wemos is calling on Pfizer and other vaccine makers to do the same for their vaccines.

Continue reading